Casos Clínicos
Total Neoadjuvant Therapy In Locally Advanced Rectal Cancer: A New Approach
Conteúdo principal do artigo
Ana Pissarra
Joana Luis
Daniela Macedo
Nuno Figueiredo
Resumo
O cancro do reto localmente avançado (LARC) é uma doença relativamente comum, com um mau prognóstico dado o seu elevado potencial metastático.
O tratamento gold standard para o LARC inclui quimiorradioterapia (QRT) seguida de cirurgia e quimioterapia adjuvante. Uma estratégia alternativa designada de tratamento neoadjuvante total (TNT) consiste na administração de QRT seguido de quimioterapia neoadjuvante antes da cirurgia, com o objetivo de dar a terapêutica sistémica de forma ininterrupta para irradicar possíveis micrometastases.
Dados recentes sugerem que a estratégia TNT oferece taxas de respostas patológicas completas superiores, com sobrevida livre de doença e sobrevida global semelhante, em comparação com a abordagem padrão. Além disso, pode permitir que um número maior de doentes entre em programas de preservação de órgão
À luz de um caso clínico, os autores revêm esta questão controversa, mas muito contemporânea.
Detalhes do artigo
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Referências
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49. doi: 10.3322/caac.21660.
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv22–iv40. doi:10.1093/annonc/mdx224
Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184-90. doi: 10.1016/S1470-2045(13)70599-0.
Breugom A, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200-7. doi: 10.1016/S1470-2045(14)71199-4.
Rodel C, Liersch T, Becker H, Fiektau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012; 13: 679–87. doi: 10.1016/S1470-2045(12)70187-0.
National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 5.2023 [accessed Jan 2022] Available at: https://fascrs.org/news/nccn-new-rectal-cancer-guideline-important-points
Petrelli F, Trevisan F, Cabiddu M, Sgroi G, Bruschieri L, Rausa E et al. Total neoadjuvant therapy in rectal cancer: A systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020; 271: 440–8. doi: 10.1097/SLA.0000000000003471.
Calmels M, Labiad C, Lelong B, Lefevre J H, Tuech JJ, Benoist S et al. Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group. Coloretal Dis. 2023;25:1973-80. doi: 10.1111/codi.16742
Contin P, Kulu Y, Bruckner T, Sturm M, Welsch T, Muller-Stich BP, et al. Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. Int J Coloretal Dis. 2014;29:165-75. doi: 10.1007/s00384-013-1780-z.
Bahadoer RR, Dijkstra EA, van Etten B, Marijnen C, Putter H, Kranenbarg E, et al. RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22: 29-42. doi: 10.1016/S1470-2045(20)30555-6.
Dijkstra E, Nilsson P, Hospers G, Bahadoer R, Kranenbarg E, Roodvoets A et al. Locoregional failure during and after short-course radiotherapy followed by Chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO Trial. Ann Surg. 2023;278:e766-72. doi: 10.1097/SLA.0000000000005799.
Conroy T, Bosset JF, Etienne PL, Rio E, François E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22: 702-15. doi: 10.1016/S1470-2045(21)00079-6.
Conroy T, Etienne PL, Rio E, François E, Mesgouez-Nebout N, Bosset JF, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J Clin Oncol. 2023;41:LBA3504. doi:10.1200/JCO.2020.38.15_suppl.4007
Giunta E F, Bregni G, Pretta A, Deleporte A, Liberale G, Bali A M, et al. Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials. Cancer Treat Rev. 2021 May:96:102177. doi: 10.1016/j.ctrv.2021.102177.
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabnbauer G, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022; 8: e215445. doi: 10.1001/jamaoncol.2021.5445.
Garcia-Aguilar J, Patil S, Gollub MJ, Kim J, Yuval J, Thompson H, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022; 40: 2546-56. doi: 10.1200/JCO.22.00032.
Pezeshki PS, Ghalehtaki R. The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer. Biomark Res. 2023;11:81. doi: 10.1186/s40364-023-00521-5.
Beppu N, Ikeda M, Kataoka K, Kimura K, Ikeuchi H, Uchino M, et al. Total Neoadjuvant Chemotherapy in Rectal Cancer: Current Facts and Future Strategies. J Anus Rectum Colon. 2023; 7: 1–7. doi: 10.23922/jarc.2022-060.
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022; 386: 2363-76. doi: 10.1056/NEJMoa2201445.
Bando H, Tsukada Y, Inamori K, Togashi Y, Koyama S, Kotani D, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. Clin Cancer Res. 2022; 28: 1136-46. doi: 10.1158/1078-0432.CCR-21-3213.
